FindTrial
Sign In

Desidustat VS Darbepoetin in anemia of chronic kidney disease patients undergoing maintenance haemodialysis

Prolyl hydroxylase inhibitor(Desidustat) VS Erythropoiesis stimulating agent(Darbepoetin) in anemia of chronic kidney disease patients undergoing maintenance haemodialysis. - Not Applicable

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/07/054621
Enrollment
60
Registered
2023-07-03
Start date
Unknown
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N185- Chronic kidney disease, stage 5

Interventions

Intervention1: DESIDUSTAT: Desidustat(HIF-prolyl hydroxylase enzyme inhibitor) work by stabilising the HIF-complex and stimulating endogenous EPO production Intervention2: NIL: NIL Control Interventio

Sponsors

Kalinga institute of medical sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Maintenance Haemodialysis Patients with Hb8-11 g/dl in chronic kidney disease.

Exclusion criteria

Exclusion criteria: Patient with iron deficiency anemia . History of Bleeding disorders. Red blood cell transfusion within 8 weeks prior to enrollment. History of previous or concurrent cancer.

Design outcomes

Primary

MeasureTime frame
Proportion of patients reaching target haemoglobin(Hb g/dl) who are receiving desidustat.Timepoint: follow up at 4weeks 8weeks & 12weeks—

Secondary

MeasureTime frame
Saftey of desidustat. Timepoint: follow up at 4weeks 8weeks 12 weeks—

Countries

India

Contacts

Public ContactChallagulla Madhu Babu

Kalinga institute of medical sciences

pankaj.khora@Kims.ac.in9178614667

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026